Surgical Site Infection and Antibiotic Use Study

Surgical Site Infection Clinical Trial

— ASSERT  

Official title:

Antibiotics and Surgical Site Infection in Expander Based Breast Reconstruction Trial (ASSERT) A Multi-institutional Randomized Controlled Trial to Determine the Optimal Antibiotic Prophylaxis for Tissue Expander-based Breast Reconstruction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04631185
• Other study ID #: PSF 19-03-SSI Study
• Status: Completed
• Phase: N/A
• Start date: May 7, 2021
• Est. completion date: May 20, 2024

Study information

• Verified date: May 2024
• Source: The Plastic Surgery Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a prospective, multi-institutional, noninferiority, randomized control trial that will compare the efficacy of two antibiotic treatments in preventing SSI in patients receiving immediate breast reconstruction with tissue expanders (TE-BR). The patients will be randomly assigned to one of the two treatment groups. One group will receive a single dose of antibiotics just before surgery and if necessary, more doses during the surgery. The other group will receive the same treatment as the first group, along with an additional week of antibiotics after surgery. The study will assess the rates of SSI from the two groups. It will also assess the type, duration and method (oral vs. intravenous) of subsequent antibiotic use for patients who develop SSIs in each group.

Description:

Among plastic surgeons, the clinical practice of prescribing postoperative prophylactic antibiotics following postmastectomy breast reconstruction with tissue expanders ranges widely from no postoperative antibiotics, to 5-7 days post-op, to antibiotics until the drains are removed. The Centers for Disease Control and Prevention (CDC) recommends a single preoperative antibiotic dose for clean and clean-contaminated procedures, even in the presence of a drain. With the CDC creating a national action plan to reduce unnecessary prophylactic antibiotics for clean non-contaminated cases by advocating use of only a single pre-operative dose of antibiotics (see: https://www.cdc.gov/drugresistance/pdf/national_action_plan_for_combating_antibotic-resistant _bacteria.pdf ) there is mounting pressure on the plastic surgery community to adopt this regimen of SSI prophylaxis. Because there are no definitive studies that provide sufficient or conclusive evidence to affect antibiotic practice patterns among plastic surgeons on a large-scale, plastic surgeons use a wide variety of protocols for their SSI prophylaxis, especially in implant-based breast reconstruction. Plastic surgeons have generally not adopted CDC guidelines because these recommendations were not based on studies in plastic surgery patients, and the use of foreign body implants underneath devitalized soft tissue can be associated with higher infection risks. Based on the literature and from self-reporting from ASPS membership, there is a wide range of prophylactic antibiotic use to prevent SSI from as little as one preoperative dose to many weeks of therapy; one week of post-operative antibiotics is the most common form. However, the Centers for Disease Control (CDC) recommends a single preoperative dose of antibiotics for clean cases, even in the presence of a drain. Prolonged antibiotic courses can lead to antibiotic complications and development of resistance.

Definitive studies to determine an optimal therapeutic strategy to prevent SSI in implant-based plastic surgical procedures are lacking. This study will address a dilemma in common plastic surgical operation: the use of post-operative antibiotics in prosthesis-based breast reconstruction.

The central hypothesis for this multi-institutional, prospective randomized control trial (RCT) is that a single pre-operative dose of intravenous antibiotics with intraoperative redosing (SPD) is no worse (noninferiority design) at preventing SSI in tissue expander-based breast reconstruction (TE-BR) than an additional week of post-operative antibiotic prophylaxis (WPO).

This trial will evaluate the efficacy of single preoperative dose versus one-week antibiotic regimens in preventing surgical site infection after tissue expander breast reconstruction. The investigators will assess the rates of SSI from the SPD vs. the WPO groups. They will assess the type, duration and method (oral vs. intravenous) of subsequent antibiotic use for patients who develop SSIs in each group. The study will also compare the readmission and premature expander removal rates due to SSI and the adverse antibiotic side effects in the two groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 235
• Est. completion date: May 20, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women 18 years or older, undergoing unilateral or bilateral mastectomy (including breast cancer, any stage, or prophylactic) and immediate tissue expander reconstruction (including submuscular, submuscular and ADM, or pre-pectoral placement).

Exclusion Criteria:

• Breast cancer patients not undergoing mastectomy

• Patients undergoing direct-to-implant reconstruction

• Patients undergoing delayed reconstruction

• Patients having autologous reconstruction

• History of radiation to the breast or chest

• History of previous breast reconstruction on the side of expander placement

• Patients with serious existing systemic infection, defined as 2 or more of the following: Peripheral body temperature >38 degrees Celsius CRP >5g/L Leukocytes > 12,000/microliter at the time of enrollment.

Related Conditions & MeSH terms

• Antibiotic Use
• Breast Reconstruction
• Communicable Diseases
• Infections
• Surgical Site Infection
• Surgical Wound Infection

Intervention

Drug:
• Single pre-operative dose of intravenous antibiotics with intraoperative redosing
Intravenous cefazolin, a cephalosporin antibiotic, will be prescribed to all patients before surgery. In case of allergy to cefazolin, intravenous clindamycin will be prescribed. For allergy to both antibiotics, an appropriate antibiotic should be chosen by the surgeon and documented. All patients will receive one dose of antibiotic within 60 minutes prior to incision, and any intraoperative doses of antibiotics according to current recommendations based on the antibiotic's dosing and on operative time.
• One week of post-operative antibiotics
The patients will be prescribed one week of Cephalosporin Antibiotic (Keflex/Duricef/Other) of their surgeon's choice.

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan
United States	Johns Hopkins University	Baltimore	Maryland
United States	The University of Chicago	Chicago	Illinois
United States	Cleveland Clinic Foundation	Cleveland	Ohio
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
The Plastic Surgery Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants in each group who develop surgical site infection (SSI) within 30 days of index procedure.	Surgical site infection as defined by CDC criteria within 30 days after the index procedure	Up to 30 days after the index procedure
Secondary	Number of participants in each group with antibiotic-related adverse events and the type of adverse events reported.	Antibiotic-related adverse events, e.g. colitis, yeast infections, anaphylaxis, etc.	Up to 30 days after the index procedure
Secondary	Number of participants in each group who develop an SSI or other complications after 30 days of index procedure.	SSI beyond 30 days after the index procedure up to the time of tissue expander exchange (for an implant or flap)	Up to two years
Secondary	Number of participants in each group who undergo premature tissue expander or implant removal.	Tissue expander or implant removal, per breast and per patient events will be calculated	From index procedure until expander removal
Secondary	Type, duration and route of antibiotic administration (Oral or Intravenous) in participants in each group who develop SSI/deep infections.	Antibiotic sensitivities in SSI/deep infections,	Up to two Years
Secondary	Comparison of any secondary infections, including resistant bacterial strains and yeast infections, in participants from the two groups who develop SSI.	Speciation of any cultures from wound or tissue samples derived from participants in each group who develop SSI will be performed	Up to two Years
Secondary	ER visit and hospital readmission rates among participants in both groups.	Length of hospitalization, need for surgery, extent of surgery (e.g. wound revision, loss of implant) will be assessed. ER visit and hospitalization rates will be recorded for comparison between the two groups	Up to two Years